---
figid: PMC6135718__nihms944158f5
figlink: /pmc/articles/PMC6135718/figure/F5/
number: F5
caption: Axitinib, Bevacizumab, Cabozantinib, Nintedanib, Pazopanib, Pegaptanib, Ramuricumab,
  Ranibizumab, Regorafenib, Sorafenib, Sunitinib, and Vandetanib are approved anti-angiogenic
  therapies that target VEGF-mediated angiogenesis. Inhibition of a VEGF ligand, a
  VEGFR binding site, or VEGFR tyrosine kinase activity leads to a reduction in angiogenesis.
  This strategy can potentially be translated for lymphangiogenesis-targeted drug
  design. Development of anti-lymphangiogenic therapies may follow the design of anti-angiogenic
  therapies by interrupting the lymphangiogenic factor VEGF-C, its receptors VEGFR2
  and VEGFR3, or the tyrosine kinase activity of VEGFR2 and VEGFR3. HA, hemangiogenic;
  LA, lymphangiogenic.
pmcid: PMC6135718
papertitle: 'Potential lymphangiogenesis therapies: learning from current anti-angiogenesis
  therapies - A review.'
reftext: Michael Yamakawa, et al. Med Res Rev. 2018 Sep;38(6):1769-1798.
pmc_ranked_result_index: '74621'
pathway_score: 0.9464964
filename: nihms944158f5.jpg
figtitle: 'Lymphangiogenesis therapies: learning from current anti-angiogenesis therapies
  - A review'
year: '2018'
organisms: Homo sapiens
ndex: 157f87af-dece-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6135718__nihms944158f5.html
  '@type': Dataset
  description: Axitinib, Bevacizumab, Cabozantinib, Nintedanib, Pazopanib, Pegaptanib,
    Ramuricumab, Ranibizumab, Regorafenib, Sorafenib, Sunitinib, and Vandetanib are
    approved anti-angiogenic therapies that target VEGF-mediated angiogenesis. Inhibition
    of a VEGF ligand, a VEGFR binding site, or VEGFR tyrosine kinase activity leads
    to a reduction in angiogenesis. This strategy can potentially be translated for
    lymphangiogenesis-targeted drug design. Development of anti-lymphangiogenic therapies
    may follow the design of anti-angiogenic therapies by interrupting the lymphangiogenic
    factor VEGF-C, its receptors VEGFR2 and VEGFR3, or the tyrosine kinase activity
    of VEGFR2 and VEGFR3. HA, hemangiogenic; LA, lymphangiogenic.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFC
  - FLT1
  - KDR
  - VEGFD
  - PGF
  - FLT4
  - VEGFA
  - VEGFB
  - TRRAP
  - Pegaptanib
  - H
  - Tyrosine
  - Axitinib
  - Cabozantinib
  - Nintedanib
  - Pazopanib
  - Regorafenib
  - Sorafenib
  - Sunitinib
  - Vandetanib
genes:
- word: VEGF-C/D
  symbol: VEGFC
  source: hgnc_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGFR-1
  symbol: VEGFR1
  source: hgnc_alias_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: (VEGFR2)
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: VEGF-C/D
  symbol: VEGF-D
  source: hgnc_alias_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGFR-3
  symbol: VEGFR3
  source: hgnc_alias_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: Trap
  symbol: TR-AP
  source: hgnc_alias_symbol
  hgnc_symbol: TRRAP
  entrez: '8295'
chemicals:
- word: Pegaptanib
  source: MESH
  identifier: C495058
- word: H
  source: MESH
  identifier: D006859
- word: Tyrosine
  source: ''
  identifier: ''
- word: Axitinib
  source: MESH
  identifier: C503983
- word: Cabozantinib
  source: MESH
  identifier: C558660
- word: Nintedanib
  source: MESH
  identifier: C530716
- word: Pazopanib
  source: MESH
  identifier: C516667
- word: Regorafenib
  source: MESH
  identifier: C559147
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Sunitinib
  source: MESH
  identifier: C473478
- word: Vandetanib
  source: MESH
  identifier: C452423
diseases: []
figid_alias: PMC6135718__F5
redirect_from: /figures/PMC6135718__F5
figtype: Figure
---
